Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M194Revenue $M0.0Net Margin (%)-303,930.0Z-Score22.8
Enterprise Value $M134EPS $-1.3Operating Margin %-303,930.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.0Pre-tax Margin (%)-243,950.0Higher ROA y-yY
Price/Book3.610-y EBITDA Growth Rate %-16.1Quick Ratio14.9Cash flow > EarningsY
Price/Sales05-y EBITDA Growth Rate %-21.4Current Ratio14.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-47.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)3ROE % (ttm)-50.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M23.1ROI % (ttm)-56.0Gross Margin Increase y-yN

Gurus Latest Trades with RPRX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found!

RPRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


RPRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Anderson KatherineCFO 2014-08-14Buy2,000$13.853.32 view
PODOLSKI JOSEPHPresident and CEO 2014-08-14Buy2,100$13.912.88 view
CAIN DANIEL FDirector 2013-11-12Buy500$14.97-4.41 view
Anderson KatherineCFO 2013-10-25Buy1,000$17.9-20.06 view
PODOLSKI JOSEPHPresident and CEO 2013-10-25Buy3,000$18.03-20.63 view
Anderson KatherineCFO 2013-10-10Buy1,000$23.77-39.8 view
Anderson KatherineCFO 2013-02-01Buy1,000$11.8920.35 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-14Buy59,500$7.3893.9 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-11Buy170,000$6.35125.35 view
PERCEPTIVE ADVISORS LLC10% Owner 2012-05-10Buy325,000$4.82196.89 view

Press Releases about RPRX :

    Quarterly/Annual Reports about RPRX:

    News about RPRX:

    Articles On GuruFocus.com
    comment on RPRX Mar 06 2013 
    Weekly CFO Buys Highlight: RPRX, ARCT, LUB, JCS, DCIN Apr 23 2012 
    promotes testosteron Jun 22 2011 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 09 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 10 2010 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) Aug 17 2009 
    Repros Therapeutics Inc. Reports Second Quarter 2009 Financial Results and Provides Update Aug 17 2009 
    Repros Therapeutics Inc. Reports Operating Results (10-Q) May 11 2009 

    More From Other Websites
    Infoblox Inc. (BLOX) Climbs On Earnings Sep 05 2014
    Repros Reports Encouraging Late-Stage Data on Androxal Aug 28 2014
    Williams-Sonoma Stumbles After Yesterday's Surge Aug 28 2014
    Why Repros Therapeutics (RPRX) Stock Is Surging Today Aug 28 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Aug 28 2014
    Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various... Aug 27 2014
    Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% Aug 22 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Aug 20 2014
    REPROS THERAPEUTICS INC. Financials Aug 19 2014
    Repros Therapeutics Q2 Loss a Penny Wider than Expected Aug 12 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition Aug 11 2014
    Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results Aug 11 2014
    Repros Gets Additional FDA Guidance for Androxal Jul 17 2014
    FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus... Jul 16 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure Jul 16 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... Jun 20 2014
    Repros Therapeutics reaches enrollment goal in second Androxal study May 13 2014
    REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure May 13 2014
    Repros' Q1 Loss In Line with Expectations May 13 2014
    Repros Therapeutics reports Q1 EPS (37c), consensus (35c) May 12 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK